Russia to organize 10 state tenders for drugs against orphan diseases

17 December 2018

The Russian Ministry of Health has announced 10 auctions for the state purchases of drugs for the treatment of orphan diseases, according to an official spokesman of the Minister of Health Veronika Skvortsova, reports The Pharma Letter’s local correspondent.

Ms Skvortsova said these tenders involve distribution of contracts for the total amount of 4 billion roubles ($60 million).

Of this amount, about 1 billion roubles will be allocated for the purchases of eculizumab, which a drug for the treatment of apathetic hemolytic-uremic syndrome. The drug is produced by the USA-based Alexion Pharmaceuticals (Nasdaq: ALXN)and is available in the Russian market under the Soliris brand.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK